| __timestamp | Alnylam Pharmaceuticals, Inc. | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 2917513 |
| Thursday, January 1, 2015 | 60610000 | 7878291 |
| Friday, January 1, 2016 | 89354000 | 8366794 |
| Sunday, January 1, 2017 | 199365000 | 6610381 |
| Monday, January 1, 2018 | 382359000 | 6556000 |
| Tuesday, January 1, 2019 | 479005000 | 6930000 |
| Wednesday, January 1, 2020 | 588420000 | 8758000 |
| Friday, January 1, 2021 | 620639000 | 10806000 |
| Saturday, January 1, 2022 | 770658000 | 9844000 |
| Sunday, January 1, 2023 | 795646000 | 13481000 |
| Monday, January 1, 2024 | 975526000 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Alnylam Pharmaceuticals, Inc. and Soleno Therapeutics, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive growth strategy. In contrast, Soleno's expenses grew by approximately 360%, indicating a more conservative approach.
Alnylam's significant increase in SG&A expenses, peaking at nearly $800 million in 2023, underscores its commitment to expanding its market presence and operational capabilities. This strategy aligns with its broader goal of pioneering RNA interference therapeutics.
Soleno, with a peak SG&A expense of around $13 million in 2023, has maintained a steady trajectory, focusing on niche markets. This approach highlights its strategic focus on sustainable growth and targeted innovation.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Soleno Therapeutics, Inc.
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Soleno Therapeutics, Inc.
Summit Therapeutics Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Jazz Pharmaceuticals plc and Soleno Therapeutics, Inc.
Comparing SG&A Expenses: Lantheus Holdings, Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and Soleno Therapeutics, Inc.
CRISPR Therapeutics AG or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Merus N.V. vs Soleno Therapeutics, Inc.: SG&A Expense Trends